Hyun W. Bae - 16 Sep 2025 Form 4 Insider Report for Kairos Pharma, LTD. (KAPA)

Reporting relationship: Director
Issuer ticker: KAPA
Reported as of: 16 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Dec 2025, 06:03:35 UTC
Prior SEC filing: 24 Sep 2024
Source filing: View source filing
Reporting owner signature: /s/ Hyun W. Bae

Key filing fact

Hyun W. Bae filed Form 4 for Kairos Pharma, LTD. (KAPA) on 23 Dec 2025.

Key facts

This page summarizes Hyun W. Bae's Form 4 filing for Kairos Pharma, LTD. (KAPA).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 23 Dec 2025, 06:03.

Change

Previous filing in this sequence was filed on 24 Sep 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001988551 Primary reporting owner

Bae Hyun W.

Relationship: Director
Address: C/O KAIROS PHARMA, LTD., 2355 WESTWOOD BLVD, #139, LOS ANGELES
Signature: /s/ Hyun W. Bae
Signature date: 23 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KAPA transaction

COMMON STOCK

Award

Transaction value: $0
Shares: +10,000
Change %: +23%
Price: $0.000000
Shares after: 54,286
Date: 16 Sep 2025
Ownership: Direct
Footnotes: F1, F2

KAPA transaction

COMMON STOCK

Award

Transaction value: $0
Shares: +19,084
Change %: +35%
Price: $0.000000
Shares after: 73,370
Date: 08 Oct 2025
Ownership: Direct
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents 10,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan (the "Plan"). The 10,000 RSUs were granted on September 16, 2024, in conjunction with the Issuer's initial public offering (IPO), and vest annually in three substantially equal installments commencing on the anniversary date of the IPO.

Footnote F2

Consists of (i) 47,620 shares of common stock and (ii) 6,666 RSUs which remain subject to vesting.

Footnote F3

Represents 19,084 RSUs issued to the Reporting Person under the Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date.

Footnote F4

Consists of (i) 54,286 shares of common stock and (ii) 19,084 RSUs which remain subject to vesting.